Zepbound is a weekly injection for chronic weight management. The medication is available in six doses through prescriptions that can be filled by retail or mail-order pharmacies, Eli Lilly said in a Dec. 5 news release.
The drug shares a main ingredient, tirzepatide, with Eli Lilly’s type 2 diabetes treatment Mounjaro, which has been widely prescribed off-label for weight loss.
On Nov. 8, the FDA approved Zepbound for obese or overweight adults who have at least one weight-related condition, such as high blood pressure or Type 2 diabetes. The drug is intended to be used alongside a reduced-calorie diet and increased physical activity.
Learn more about Zepbound here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.